Antiproliferative and Apoptotic Effect of Curcumin and TRAIL (TNF Related Apoptosis Inducing Ligand) in Chronic Myeloid Leukaemic Cells

Overview

Journal J Clin Diagn Res

Specialty General Medicine

Date 2016 May 19

PMID 27190933

Citations 6

Authors

Bushra Iqbal

Archna Ghildiyal

Sahabjada

Shraddha Singh

Mohd Arshad

Abbas Ali Mahdi

Sunita Tiwari

Affiliations

Soon will be listed here.

Abstract

Introduction: Curcumin, traditionally utilized as a flavouring zest as a part of Indian cooking, has been accounted to decrease the proliferation potential of most cancer cells. Apoptosis is a mechanism by which most anticancer therapies including chemotherapy, radiation and antihormonal therapy kill tumour/cancer cells. Novel agents that may sensitize drug-resistant tumour cells for induction of apoptosis by customary treatments could lead to the regression and improved prognosis of the refractory disease. Indeed, chemotherapeutic agents have been shown to sensitize cancer cells to killing by death ligands such as tumour necrosis factor-α.

Aim: To investigate cytotoxicity and apoptotic effect of curcumin in chronic myeloid leukaemic cell line KCL-22.

Materials And Methods: In present study, different doses of curcumin (10,25,50,75,100μM) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) (25,50 μM) alone and combine regimen were exposed to myeloid leukaemic cell KCL-22. The cell viability was monitored by MTT assay, apoptotic activity by binding of Annexin V-FITC using fluorescence microscopy and cell cycle check points by flow cytometry.

Results: Cytotoxic assay revealed that curcumin and TRAIL induced both dose and time-dependent decrease in cell viability. Significant cell cytotoxicity was seen in combine regimen of both curcumin and TRAIL at 48 h of exposure. Cells treated with curcumin and TRAIL was arrested at the S phase, as revealed by flow cytometric analysis. Subtoxic concentrations of the curcumin-TRAIL combination induced strong apoptotic response in KCL-22 cells as demonstrated by the binding of Annexin V-FITC.

Conclusion: Our study conclude that curcumin inhibits the cancer cell growth by inducing apoptosis and enhance the therapeutic potential of TRAIL which recommends that both curcumin alone or in combination with TRAIL might be useful for leukaemic prevention and better therapeutic responses.

Citing Articles

Curcumin Sensitizes Kidney Cancer Cells to TRAIL-Induced Apoptosis via ROS Mediated Activation of JNK-CHOP Pathway and Upregulation of DR4.

Obaidi I, Cassidy H, Ibanez Gaspar V, McCaul J, Higgins M, Halasz M Biology (Basel). 2020; 9(5).

PMID: 32370057 PMC: 7284747. DOI: 10.3390/biology9050092.

Epigallocatechin-3-Gallate Induces Apoptosis as a TRAIL Sensitizer via Activation of Caspase 8 and Death Receptor 5 in Human Colon Cancer Cells.

Kwon O, Jung J, Shin E, Park J, Park W, Kim S Biomedicines. 2020; 8(4).

PMID: 32283836 PMC: 7235876. DOI: 10.3390/biomedicines8040084.

Curcumin inhibits MCF-7 cells by modulating the NF-κB signaling pathway.

Liu J, Pan Y, Chen O, Luan Y, Xue X, Zhao J Oncol Lett. 2017; 14(5):5581-5584.

PMID: 29142607 PMC: 5666651. DOI: 10.3892/ol.2017.6860.

Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study.

Chang L, Hsieh M, Yang J, Lu C, Tsai F, Tsao J Int J Oncol. 2017; 52(1):67-76.

PMID: 29138806 PMC: 5743386. DOI: 10.3892/ijo.2017.4204.

Combination of metformin and curcumin targets breast cancer in mice by angiogenesis inhibition, immune system modulation and induction of p53 independent apoptosis.

Falah R, Talib W, Shbailat S Ther Adv Med Oncol. 2017; 9(4):235-252.

PMID: 28491145 PMC: 5405996. DOI: 10.1177/1758834016687482.

References

Bae M, Kim S, Jeong J, Lee Y, Kim H, Kim S . Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep. 2006; 15(6):1557-62. View

RUDKIN C, HUNGERFORD D, Nowell P . DNA CONTENTS OF CHROMOSOME PH1 AND CHROMOSOME 21 IN HUMAN CHRONIC GRANULOCYTIC LEUKEMIA. Science. 1964; 144(3623):1229-31. DOI: 10.1126/science.144.3623.1229. View

Faderl S, Talpaz M, Estrov Z, OBrien S, Kurzrock R, Kantarjian H . The biology of chronic myeloid leukemia. N Engl J Med. 1999; 341(3):164-72. DOI: 10.1056/NEJM199907153410306. View

Lin Y, Kunnumakkara A, Nair A, Merritt W, Han L, Armaiz-Pena G . Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res. 2007; 13(11):3423-30. DOI: 10.1158/1078-0432.CCR-06-3072. View

Deeb D, Xu Y, Jiang H, Gao X, Janakiraman N, Chapman R . Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther. 2003; 2(1):95-103. View

Deeb D, Jiang H, Gao X, Hafner M, Wong H, Divine G . Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther. 2004; 3(7):803-12. View

Nakajima Y, DelliPizzi A, Mallouh C, Ferreri N . Effect of tumor necrosis factor-alpha and interferon-gamma on the growth of human prostate cancer cell lines. Urol Res. 1995; 23(4):205-10. DOI: 10.1007/BF00393299. View

Aggarwal S, Ichikawa H, Takada Y, Sandur S, Shishodia S, Aggarwal B . Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol. 2005; 69(1):195-206. DOI: 10.1124/mol.105.017400. View

Sun S, Yue P, Hong W, Lotan R . Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human.... Cancer Res. 2001; 60(24):7149-55. View

10.

Anto R, Mukhopadhyay A, Denning K, Aggarwal B . Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis. 2002; 23(1):143-50. DOI: 10.1093/carcin/23.1.143. View

11.

Borner M, Myers C, Sartor O, Sei Y, Toko T, Trepel J . Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res. 1995; 55(10):2122-8. View

12.

MacFarlane M, Ahmad M, Srinivasula S, Fernandes-Alnemri T, Cohen G, Alnemri E . Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem. 1997; 272(41):25417-20. DOI: 10.1074/jbc.272.41.25417. View

13.

Schmidt U, van den Akker E, Parren-van Amelsvoort M, Litos G, de Bruijn M, Gutierrez L . Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors. J Exp Med. 2004; 199(6):785-95. PMC: 2212722. DOI: 10.1084/jem.20031109. View

14.

Plasilova M, Zivny J, Jelinek J, Neuwirtova R, cermak J, Necas E . TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia. 2002; 16(1):67-73. DOI: 10.1038/sj.leu.2402338. View

15.

Zamai L, Secchiero P, Pierpaoli S, Bassini A, Papa S, Alnemri E . TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood. 2000; 95(12):3716-24. View

16.

Zang D, Goodwin R, Loken M, Bryant E, Deeg H . Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood. 2001; 98(10):3058-65. DOI: 10.1182/blood.v98.10.3058. View

17.

Devasena T, Rajasekaran K, Gunasekaran G, Viswanathan P, Menon V . Anticarcinogenic effect of bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione a curcumin analog on DMH-induced colon cancer model. Pharmacol Res. 2003; 47(2):133-40. DOI: 10.1016/s1043-6618(02)00283-9. View

18.

Aggarwal B, Sung B . Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2008; 30(2):85-94. DOI: 10.1016/j.tips.2008.11.002. View

19.

Yoysungnoen P, Wirachwong P, Bhattarakosol P, Niimi H, Patumraj S . Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin Hemorheol Microcirc. 2006; 34(1-2):109-15. View

20.

Pitti R, Marsters S, Ruppert S, Donahue C, Moore A, Ashkenazi A . Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996; 271(22):12687-90. DOI: 10.1074/jbc.271.22.12687. View